Cited by 268Psoriasis: Treatment and PathogenesisCytokine Signaling Pathways and InteractionsT-cell and B-cell Immunology

IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state

Nishihara, Mika, Ogura, Hideki, Ueda, Naoko, Tsuruoka, Mineko, Kitabayashi, Chika, Tsuji, Fumio, Aono, Hiroyuki, Ishihara, Katsuhiko +4 more·2007·International Immunology

Abstract

IL-17-producing Th (Th17) comprise a distinct lineage of pro-inflammatory Th that are major contributors to autoimmune diseases. Treatment with IL-6 and transforming growth factor beta (TGFbeta) induces naive CD4+ T cells to generate Th17, which also requires expression of the IL-6/TGFbeta target RORgammat. We reported that IL-6 transduces two signaling pathways via tyrosine redidues of the signal transducer gp130: one depends on signal transducers and activators of transcription (STAT)-3 activation and the other on Src homology region 2 domain-containing phosphatase 2 (SHP2)/Grb2 associated binder (Gab)/mitogen-activated protein kinase (MAPK) activation. Here, we showed that CD4+ T cells carrying a mutant gp130 that transduces the SHP2/Gab/MAPK pathway but not the STAT3-mediated one failed to develop into Th17, while CD4+ T cells whose mutant gp130 transduces the STAT3 signal only generated Th17, indicating that IL-6 acts directly on T cells through the tyrosine residues of gp130 required for STAT3 activation to promote the development of Th17. Moreover, we found that gp130-STAT3 pathway is essential for Th17 development and for the expression of RORgammat by using T cells specifically lacking gp130 and STAT3. Noteworthy is that the regulatory T cell (Treg) percentages and numbers were comparable between all mutant mice we tested in vivo, although we showed that IL-6-gp130-STAT3 pathway suppressed Treg development in vitro. Thus, we conclude that IL-6 acts directly to promote the development of Th17 by activating the T cell gp130-STAT3 pathway but has a minimum effect on Treg development at least in the steady state in vivo. Therefore, blockade of IL-6-gp130-STAT3 pathway in CD4+ T cells could be a good target for controlling unwanted Th17-mediated immune responses including autoimmune diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/intimm/dxm045

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • STAT3 activated by IL-6, IL-21, and IL-23 upregulates RORγt, RORα, IL-21, IL-23R, and IL-17, helping development and stabilization of Th17 cells.

    “STAT3 activated by several proinflammatory cytokines, e.g., IL-6, IL-21, and IL-23, upregulates RORγt, RORα, IL-21, IL-23R, and IL-17, thereby helping in the development and stabilization of Th17 cells”

    From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Nishihara et al., 2007

    The Introduction and the section on gp130 STAT3-binding residues report that IL-6–gp130–STAT3 signaling promotes RORγt expression and Th17 development. The latter section only suggests that STAT3 might induce IL-17 mRNA; our copy does not establish the claimed STAT3-mediated upregulation of RORα, IL-21, or IL-23R, activation by IL-21 or IL-23, or stabilization of Th17 cells. Page numbers were not provided. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Bacon, C. M., Petricoin, E. F.I., Ortaldo, J. R. et al. 1995. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc. Natl Acad. Sci. USA 92:7307.
  2. Chen, Z., Laurence, A., Kanno, Y. et al. 2006. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc. Natl Acad. Sci. USA 103:8137.

Cited by

Sorted by citations

Authors
Nishihara, M., Ogura, H., Ueda, N., Tsuruoka, M., Kitabayashi, C., Tsuji, F., Aono, H., Ishihara, K., Huseby, E., Betz, U. A. K., Murakami, M., & Hirano, T.
Affiliations
  • The University of Osaka (JP)
  • Santen (Japan) (JP)
  • University of Massachusetts Chan Medical School (US)
  • Merck KGaA, Darmstadt (Germany) (DE)
  • RIKEN (JP)
Venue
International Immunology
Published
2007-05-09
Volume
19
Issue
6
Pages
695-702
ISSN
  • 0953-8178 (ISSN-L)
  • 1460-2377
OpenAlex
W2159451122
Cited by
268
References
8
Citations by year
2026: 12 · 2025: 10 · 2024: 15 · 2023: 5 · 2022: 15 · 2021: 6 · 2020: 11 · 2019: 12 · 2018: 17 · 2017: 15 · 2016: 9 · 2015: 17 · 2014: 10 · 2013: 24 · 2012: 12
FWCI
6.95
Type
journal article
Language
en
Open access
closed
Locations
  • International Immunology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Ministry of Education, Culture, Sports, Science and Technology
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
interleukin-6, gp130, STAT3, Th17 cells, regulatory T cells, CD4+ T cells, RORγ, TGF-beta, IL-6 signaling, autoimmune disease, T cell differentiation
MeSH terms
Animals, Arthritis, Experimental, Cell Count, Cell Differentiation, Flow Cytometry, T-Lymphocytes, Helper-Inducer, Lymph Nodes, Lymphocyte Activation, Mice, Inbred C57BL, Mice, Inbred DBA, Mice, Transgenic, Receptors, Thyroid Hormone, Spleen, Signal Transduction, CD4-Positive T-Lymphocytes, Interleukin-6, Receptors, Retinoic Acid, Mice, Knockout, Interleukin-17, T-Lymphocytes, Regulatory, STAT3 Transcription Factor, Cytokine Receptor gp130, Mice, Forkhead Transcription Factors, Nuclear Receptor Subfamily 1, Group F, Member 3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review